Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities
New England Journal of Medicine · 22.02.2024 · 390 (8) · 677-680
DOI: 10.1056/nejmp2312816 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 22.02.2024. Verfasst von Ilya Golovaty und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the VA Puget Sound Health Care System (I.G., S.H.), and the Division of General Internal Medicine, University of Washington (I.G., S.H.) - both …. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- From the VA Puget Sound Health Care System (I.G., S.H.), and the Division of General Internal Medicine, University of Washington (I.G., S.H.) - both in Seattle.
ORCID-Profile: Ilya Golovaty, Scott Hagan
Zitieren
APA
Golovaty, I., & Hagan, S. (2024). Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities. New England Journal of Medicine, 390(8), 677-680. https://doi.org/10.1056/nejmp2312816
Vancouver
Golovaty I, Hagan S. Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities. New England Journal of Medicine. 2024;390(8):677-680. doi:10.1056/nejmp2312816
BibTeX
@article{Golovaty2024,
author = {Golovaty, Ilya and Hagan, Scott},
title = {Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {8},
pages = {677--680},
doi = {10.1056/nejmp2312816}
}
EUVIMED